Dr. De Santis on the Future Treatment Landscape for Bladder Cancer

Maria De Santis, MD
Published: Thursday, Oct 05, 2017



Maria De Santis, MD, associate clinical professor at the University of Warwick, discusses the future treatment landscape for patients with bladder cancer.

In the future, we should differentiate between surgery, radiotherapy, and medical oncology, states De Santis.

There has been an improvement in overall survival in the second-line treatment compared to chemotherapy, and this field will expand further with new studies evaluating combinations of immunotherapy and combinations of chemotherapy with immunotherapy, as well.
 


Maria De Santis, MD, associate clinical professor at the University of Warwick, discusses the future treatment landscape for patients with bladder cancer.

In the future, we should differentiate between surgery, radiotherapy, and medical oncology, states De Santis.

There has been an improvement in overall survival in the second-line treatment compared to chemotherapy, and this field will expand further with new studies evaluating combinations of immunotherapy and combinations of chemotherapy with immunotherapy, as well.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x